Kathryn Dolores Simms, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Eden Medical Center · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Kathryn Dolores Simms’s office at (650) 723-4000 to ask if they take your plan before you enroll.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$2,000,473
Medicare paid this office $2,000,473 for 355 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 15 | $545,541 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 44 | $79,656 | None |
| Injection, denosumab, 1 mg | 22 | $74,725 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 12 | $48,083 | None |
| Injection, ferric carboxymaltose, 1 mg | 30 | $27,084 | None |
See all 34 services
| Injection, pembrolizumab, 1 mg | 15 | $545,541 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 44 | $79,656 | None |
| Injection, denosumab, 1 mg | 22 | $74,725 | None |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 12 | $48,083 | None |
| Injection, ferric carboxymaltose, 1 mg | 30 | $27,084 | None |
| Administration of chemotherapy into vein, 1 hour or less | 57 | $23,160 | $118 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 17 | $17,600 | None |
| Short return visit (20+ min) | 89 | $10,227 | $72 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $9,594 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 50 | $5,771 | $56 |
| Return visit (30+ min) | 43 | $5,228 | $95 |
| Injection of additional new drug or substance into vein | 79 | $4,981 | $13 |
| Long return visit (40+ min) | 31 | $4,926 | $145 |
| Administration of additional new drug or substance into vein, 1 hour or less | 27 | $4,294 | $57 |
| Injection of drug or substance under skin or into muscle | 102 | $3,707 | $12 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 215 | $3,607 | $8 |
| Injection of drug or substance into vein | 27 | $1,606 | $33 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 20 | $1,444 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 28 | $1,335 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 17 | $1,248 | $18 |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $1,217 | $28 |
| Administration of chemotherapy into vein, each additional hour | 17 | $944 | $24 |
| Injection, carboplatin, 50 mg | 16 | $635 | None |
| Injection, fosaprepitant, 1 mg | 18 | $635 | None |
| Injection, palonosetron hcl, 25 mcg | 24 | $456 | None |
| Injection, zoledronic acid, 1 mg | 12 | $430 | None |
| Application of on-body injector for under skin injection | 14 | $410 | $16 |
| Insertion of needle into vein for collection of blood sample | 33 | $389 | $9 |
| Injection, paclitaxel, 1 mg | 12 | $370 | None |
| Infusion into a vein for hydration, each additional hour | 13 | $354 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 65 | $161 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $58 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $54 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 21 | $34 | None |
Who their Medicare patients are
355 Original Medicare patients in 2024. Average age 76 · Under 65 8% · 85 and older 16% · Women 56% · Also on Medicaid 30% · Health risk score 2.02. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 75% · Chronic kidney disease 46% · Diabetes 40% · Cancer 39% · Coronary heart disease 29% · Heart failure 22% · Depression 22% · Atrial fibrillation 19% · COPD 17% · Stroke 12% · Dementia 8%.
The office billed $15,103,759, Medicare allowed $2,509,927 and paid $2,000,473; for 155,011 services of 99 kinds; $1,908,546 of it was for drugs given in the office and $91,928 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 355 | 155,011 | 76 | 2.02 | $15,103,759 | $2,000,473 |
| 2023 | 288 | 108,429 | 75 | 2.04 | $6,507,175 | $1,362,478 |
| 2022 | 105 | 14,718 | 76 | 1.99 | $1,219,929 | $270,030 |
| 2021 | 80 | 175 | 72 | 2.52 | $125,751 | $18,121 |
| 2020 | 11 | 14 | 76 | 4.55 | $4,590 | $938 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 25 services
| Injection, denosumab, 1 mg | 21 | $52,783 | None |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 25 | $44,665 | None |
| Injection, ferric carboxymaltose, 1 mg | 25 | $23,607 | None |
| Administration of chemotherapy into vein, 1 hour or less | 50 | $23,524 | $117 |
| Return visit (30+ min) | 48 | $7,619 | $86 |
| Short return visit (20+ min) | 71 | $6,628 | $68 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 32 | $4,390 | $57 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 203 | $4,249 | $8 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $3,786 | $57 |
| Injection of additional new drug or substance into vein | 58 | $3,738 | $13 |
| Long return visit (40+ min) | 15 | $2,348 | $138 |
| Injection of drug or substance under skin or into muscle | 67 | $2,048 | $12 |
| Drawing of blood for a medical problem | 16 | $1,686 | $89 |
| Administration of chemotherapy into vein, each additional hour | 22 | $1,196 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 16 | $1,110 | $25 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $860 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 14 | $841 | $18 |
| Injection of drug or substance into vein | 19 | $722 | $33 |
| Infusion into a vein for hydration, 31-60 minutes | 15 | $604 | $29 |
| Injection, fosaprepitant, 1 mg | 11 | $457 | None |
| Injection, palonosetron hcl, 25 mcg | 18 | $393 | None |
| Infusion into a vein for hydration, each additional hour | 13 | $242 | $11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 47 | $102 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $66 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 15 | $40 | None |
2022: 7 services
| Administration of chemotherapy into vein, 1 hour or less | 19 | $4,586 | $121 |
| Return visit (30+ min) | 22 | $2,534 | $101 |
| Long return visit (40+ min) | 11 | $1,188 | $91 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 59 | $609 | $8 |
| Injection of additional new drug or substance into vein | 11 | $586 | $14 |
| Injection of drug or substance under skin or into muscle | 13 | $175 | $12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $17 | None |
2021: 1 service
| Long return visit (40+ min) | 69 | $16,683 | $111 |
Drugs they prescribed that Part D paid
$3,508,664
Pharmacies billed $3,508,664 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (100 of 1,381) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%. Long-acting opioids: 28% of their opioid prescriptions.
1,033 generic and fewer than 11 brand-name prescriptions · $3,508,664 in drug cost · 12 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Revlimid | 31 | $594,503 | $19,178 |
| Tagrisso | 14 | $523,782 | $37,413 |
| Brukinsa | 36 | $480,248 | $13,340 |
| Xtandi | 32 | $422,061 | $13,189 |
| Pomalyst | 12 | $276,665 | $23,055 |
See all 37 drugs
| Revlimid | 31 | $594,503 | $19,178 |
| Tagrisso | 14 | $523,782 | $37,413 |
| Brukinsa | 36 | $480,248 | $13,340 |
| Xtandi | 32 | $422,061 | $13,189 |
| Pomalyst | 12 | $276,665 | $23,055 |
| Imbruvica | 22 | $245,465 | $11,157 |
| Alecensa | 13 | $178,856 | $13,758 |
| Vonjo | 13 | $158,472 | $12,190 |
| Eliquis | 105 | $65,977 | $628 |
| Xarelto | 19 | $19,420 | $1,022 |
| Abiraterone Acetate | 14 | $3,067 | $219 |
| Tamoxifen Citrate | 81 | $1,656 | $20 |
| Prochlorperazine Maleate | 63 | $1,339 | $21 |
| Entecavir | 12 | $1,221 | $102 |
| Ondansetron | 46 | $1,190 | $26 |
| Gabapentin | 59 | $1,183 | $20 |
| Mirtazapine | 48 | $777 | $16 |
| Hydrocodone-Acetaminophen | 36 | $706 | $20 |
| Morphine Sulfate Er | 18 | $682 | $38 |
| Hydroxyurea | 49 | $602 | $12 |
| Letrozole | 34 | $572 | $17 |
| Anastrozole | 21 | $563 | $27 |
| Dexamethasone | 44 | $492 | $11 |
| Acyclovir | 38 | $393 | $10 |
| Oxycodone | 16 | $316 | $20 |
| Ondansetron Odt | 16 | $270 | $17 |
| Pantoprazole | 21 | $220 | $10 |
| Folic Acid | 15 | $162 | $11 |
| Prednisone | 34 | $143 | $4 |
| Trazodone | 26 | $126 | $5 |
| Alendronate | 28 | $107 | $4 |
| Lorazepam | 27 | $94 | $3 |
| Montelukast | 21 | $93 | $4 |
| Alprazolam | 14 | $80 | $6 |
| Allopurinol | 12 | $72 | $6 |
| Amlodipine Besylate | 12 | $55 | $5 |
| Venlafaxine Hcl Er | 12 | $42 | $4 |
Year by year
| 2024 | 1,381 | 279 | 7% (100) | None | $3,508,664 |
| 2023 | 994 | 224 | 12% (114) | None | $2,253,335 |
| 2022 | 202 | 89 | 9% (18) | 36% | $905,632 |
| 2021 | 326 | 101 | 10% (32) | None | $743,551 |
| 2020 | 388 | 110 | 11% (41) | None | $1,180,766 |
| 2019 | 241 | 70 | 12% (28) | 20% | $491,055 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 32 drugs
| Revlimid | 22 | $455,888 | $20,722 |
| Xtandi | 24 | $342,851 | $14,285 |
| Brukinsa | 14 | $212,052 | $15,147 |
| Imbruvica | 17 | $211,033 | $12,414 |
| Abiraterone Acetate | 13 | $63,423 | $4,879 |
| Eliquis | 44 | $34,181 | $777 |
| Orgovyx | 11 | $32,512 | $2,956 |
| Imatinib Mesylate | 17 | $23,881 | $1,405 |
| Xarelto | 11 | $13,451 | $1,223 |
| Exemestane | 14 | $4,011 | $287 |
| Tamoxifen Citrate | 68 | $2,322 | $34 |
| Letrozole | 41 | $1,496 | $36 |
| Hydrocodone-Acetaminophen | 50 | $1,449 | $29 |
| Mirtazapine | 32 | $1,032 | $32 |
| Entecavir | 12 | $917 | $76 |
| Anastrozole | 24 | $854 | $36 |
| Morphine Sulfate Er | 17 | $683 | $40 |
| Gabapentin | 54 | $621 | $11 |
| Prochlorperazine Maleate | 13 | $379 | $29 |
| Oxycodone | 14 | $377 | $27 |
| Prednisone | 29 | $348 | $12 |
| Trazodone | 30 | $308 | $10 |
| Hydroxyurea | 12 | $290 | $24 |
| Pantoprazole | 20 | $284 | $14 |
| Ondansetron | 11 | $247 | $22 |
| Ondansetron Odt | 11 | $209 | $19 |
| Acyclovir | 18 | $202 | $11 |
| Dexamethasone | 20 | $163 | $8 |
| Sertraline | 15 | $136 | $9 |
| Alendronate | 12 | $135 | $11 |
| Zolpidem | 12 | $121 | $10 |
| Lorazepam | 28 | $121 | $4 |
2022: 3 drugs
| Tagrisso | 34 | $550,413 | $16,189 |
| Eliquis | 18 | $9,976 | $554 |
| Hydrocodone-Acetaminophen | 12 | $379 | $32 |
2021: 6 drugs
| Zenpep | 15 | $64,379 | $4,292 |
| Eliquis | 22 | $11,269 | $512 |
| Ondansetron | 25 | $1,043 | $42 |
| Mirtazapine | 12 | $547 | $46 |
| Oxycodone | 16 | $338 | $21 |
| Lorazepam | 13 | $62 | $5 |
2020: 8 drugs
| Tagrisso | 24 | $356,802 | $14,867 |
| Abiraterone Acetate | 17 | $162,899 | $9,582 |
| Enoxaparin | 21 | $5,417 | $258 |
| Dronabinol | 11 | $2,219 | $202 |
| Ondansetron | 16 | $697 | $44 |
| Oxycodone | 20 | $526 | $26 |
| Hydrocortisone | 13 | $341 | $26 |
| Prednisone | 25 | $133 | $5 |
2019: 4 drugs
| Tagrisso | 17 | $262,366 | $15,433 |
| Prochlorperazine Maleate | 37 | $1,594 | $43 |
| Ondansetron | 34 | $880 | $26 |
| Dexamethasone | 23 | $674 | $29 |
Money from drug and device companies
$53 in 2025
| 2025 | 2 | 2 | None | $53 |
| 2024 | 5 | 5 | None | $113 |
| 2023 | 8 | 11 | None | $325 |
| 2022 | 3 | 3 | None | $85 |
| 2021 | 1 | 2 | None | $235 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Daiichi Sankyo | Enhertu | $30 | 1 payment
|
| Celgene | Reblozyl | $23 | 1 payment
|
See all 2 published payments
| Daiichi Sankyo | Meals · 2025-11-02 | Enhertu | $30 |
| Celgene | Meals · 2025-06-27 | Reblozyl | $23 |
See earlier years (2024, 2023, 2022, 2021)
2024: $113
| Celgene | Pomalyst | $29 | 1 payment
|
| Eisai | Lenvima | $24 | 1 payment
|
| Coherus Biosciences | Udenyca | $23 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $22 | 1 payment
|
| Pfizer | Bosulif | $16 | 1 payment
|
2023: $325
| Daiichi Sankyo | Injectafer | $98 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $91 | 1 payment
|
| Seagen | Tukysa | $27 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $26 | 1 payment
|
| Novartis Pharmaceuticals | None | $24 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $21 | 1 payment
|
| Coherus Biosciences | Udenyca | $19 | 1 payment
|
| Novocure | Optune | $18 | 1 payment
|
2022: $85
| AstraZeneca Pharmaceuticals LP | None | $50 | 1 payment
|
| Daiichi Sankyo | Injectafer | $22 | 1 payment
|
| Coherus Biosciences | Udenyca | $13 | 1 payment
|
2021: $235
| Takeda Pharmaceuticals U.S.A. | Exkivity | $235 | 2 payments
|
Professional record
- NPI
- 1447770359
- Licence
- CA 95016506
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 20055 Lake Chabot Rd Ste 130, Castro Valley, CA, 94546
- NPI first listed
- 2017-06-21
- NPI last updated
- 2024-02-01
- NPI record certified
- 2024-02-01
This is when the NPI record was last certified, not a medical board exam.